158 related articles for article (PubMed ID: 35165969)
1. The representation of females in clinical trials for substance use disorder conducted in the United States (2010-19).
Gunn CM; Pankowska M; Harris M; Helsing E; Battaglia TA; Bagley SM
Addiction; 2022 Oct; 117(10):2583-2590. PubMed ID: 35165969
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Functional and structural social support, substance use and sexual orientation from a nationally representative sample of US adults.
Kahle EM; Veliz P; McCabe SE; Boyd CJ
Addiction; 2020 Mar; 115(3):546-558. PubMed ID: 31599027
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and Co-occurrence of Alcohol, Nicotine, and Other Substance Use Disorder Diagnoses Among US Transgender and Cisgender Adults.
Hughto JMW; Quinn EK; Dunbar MS; Rose AJ; Shireman TI; Jasuja GK
JAMA Netw Open; 2021 Feb; 4(2):e2036512. PubMed ID: 33538824
[TBL] [Abstract][Full Text] [Related]
5. Impact of implementing a tobacco and recreational nicotine-free policy and enhanced treatments on programmatic and patient-level outcomes within a residential substance use disorder treatment program.
Hemmy Asamsama O; Miller SC; Silvestri MM; Bonanno C; Krondilou K
J Subst Abuse Treat; 2019 Dec; 107():44-49. PubMed ID: 31757264
[TBL] [Abstract][Full Text] [Related]
6. Need for and Receipt of Substance Use Disorder Treatment Among Adults, by Gender, in the United States.
Martin CE; Parlier-Ahmad AB; Beck L; Scialli A; Terplan M
Public Health Rep; 2022; 137(5):955-963. PubMed ID: 34546835
[TBL] [Abstract][Full Text] [Related]
7. Cigarette use is increasing among people with illicit substance use disorders in the United States, 2002-14: emerging disparities in vulnerable populations.
Weinberger AH; Gbedemah M; Wall MM; Hasin DS; Zvolensky MJ; Goodwin RD
Addiction; 2018 Apr; 113(4):719-728. PubMed ID: 29265574
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Female Enrollment and Participant Sex by Burden of Disease in US Clinical Trials Between 2000 and 2020.
Steinberg JR; Turner BE; Weeks BT; Magnani CJ; Wong BO; Rodriguez F; Yee LM; Cullen MR
JAMA Netw Open; 2021 Jun; 4(6):e2113749. PubMed ID: 34143192
[TBL] [Abstract][Full Text] [Related]
9. Utilization of addiction treatment among U.S. adults with history of incarceration and substance use disorders.
Tsai J; Gu X
Addict Sci Clin Pract; 2019 Mar; 14(1):9. PubMed ID: 30836991
[TBL] [Abstract][Full Text] [Related]
10. Personality disorders and the 3-year course of alcohol, drug, and nicotine use disorders.
Hasin D; Fenton MC; Skodol A; Krueger R; Keyes K; Geier T; Greenstein E; Blanco C; Grant B
Arch Gen Psychiatry; 2011 Nov; 68(11):1158-67. PubMed ID: 22065531
[TBL] [Abstract][Full Text] [Related]
11. The 3-Year Course of Multiple Substance Use Disorders in the United States: A National Longitudinal Study.
McCabe SE; West BT
J Clin Psychiatry; 2017 May; 78(5):e537-e544. PubMed ID: 28406266
[TBL] [Abstract][Full Text] [Related]
12. Substance use disorders and the risk of suicide mortality among men and women in the US Veterans Health Administration.
Bohnert KM; Ilgen MA; Louzon S; McCarthy JF; Katz IR
Addiction; 2017 Jul; 112(7):1193-1201. PubMed ID: 28301070
[TBL] [Abstract][Full Text] [Related]
13. DSM-5 substance use disorders among adult primary care patients: Results from a multisite study.
Wu LT; McNeely J; Subramaniam GA; Brady KT; Sharma G; VanVeldhuisen P; Zhu H; Schwartz RP
Drug Alcohol Depend; 2017 Oct; 179():42-46. PubMed ID: 28753480
[TBL] [Abstract][Full Text] [Related]
14. Medical Costs of Substance Use Disorders in the US Employer-Sponsored Insurance Population.
Li M; Peterson C; Xu L; Mikosz CA; Luo F
JAMA Netw Open; 2023 Jan; 6(1):e2252378. PubMed ID: 36692881
[TBL] [Abstract][Full Text] [Related]
15. Estimating demand for primary care-based treatment for substance and alcohol use disorders.
Barry CL; Epstein AJ; Fiellin DA; Fraenkel L; Busch SH
Addiction; 2016 Aug; 111(8):1376-84. PubMed ID: 26899802
[TBL] [Abstract][Full Text] [Related]
16. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
17. Deployment of personnel to military operations: impact on mental health and social functioning.
Bøg M; Filges T; Jørgensen AMK
Campbell Syst Rev; 2018; 14(1):1-127. PubMed ID: 37131363
[TBL] [Abstract][Full Text] [Related]
18. High Risk of Alcohol-Impaired Driving in Adults With Comorbid Alcohol and Substance Use Disorders in the U.S. Population.
Roberts W; Moore KE; Pittman BP; Fillmore MT; McKee SA
J Stud Alcohol Drugs; 2019 Jan; 80(1):114-119. PubMed ID: 30807283
[TBL] [Abstract][Full Text] [Related]
19. Persistence/recurrence of and remission from DSM-5 substance use disorders in the United States: Substance-specific and substance-aggregated correlates.
McCabe SE; West BT; Strobbe S; Boyd CJ
J Subst Abuse Treat; 2018 Oct; 93():38-48. PubMed ID: 30126540
[TBL] [Abstract][Full Text] [Related]
20. Substance Use Disorders Among Veterans in a Nationally Representative Sample: Prevalence and Associated Functioning and Treatment Utilization.
Boden MT; Hoggatt KJ
J Stud Alcohol Drugs; 2018 Nov; 79(6):853-861. PubMed ID: 30573015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
